Search

Your search keyword '"Zhukova, Nataliya"' showing total 327 results

Search Constraints

Start Over You searched for: Author "Zhukova, Nataliya" Remove constraint Author: "Zhukova, Nataliya"
327 results on '"Zhukova, Nataliya"'

Search Results

51. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study

56. Hepatoprotective Effect of a New FFAR1 Agonist—N-Alkylated Isobornylamine.

57. 9-N-n-alkyl Berberine Derivatives: Hypoglycemic Activity Evaluation.

70. Environmentally friendly and efficient method for the synthesis of the newα,α′‐diimine ligands with benzimidazole moiety

71. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas

73. 3‐(α‐Chlorobenzyl)quinoxalin‐2(1 H )‐ones as Versatile Reagents for the Synthesis of 3‐Benzylquinoxalin‐2(1 H )‐ones and Thiazolo[3,4‐ a ]quinoxalin‐4(5 H )‐ones

75. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.

77. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue

78. Environmentally friendly and efficient method for the synthesis of the new α,α′‐diimine ligands with benzimidazole moiety.

79. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma

80. One-Pot Synthesis of 7-(Benzimidazol-2-yl)thioxolumazine and -lumazine Derivatives via H2SO4-Catalyzed Rearrangement of Quinoxalinones When Exposed to 5,6-Diamino-2-mercapto- and 2,5,6-Triaminopyrimidin-4-ols

81. 'ЕЛЕГАНТНІСТЬ ЇЖАЧКА' МЮРІЕЛЬ БАРБЕРІ: МЕТАФІЗИКА ЧИ ПРОТОКУЛЬТУРА?

82. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas

83. LGG-18. MOLECULAR ALTERATIONS PREDICT RESPONSE TO CHEMOTHERAPY AND OUTCOME OF PEDIATRIC LOW-GRADE GLIOMA

84. 3‐(α‐Chlorobenzyl)quinoxalin‐2(1H)‐ones as Versatile Reagents for the Synthesis of 3‐Benzylquinoxalin‐2(1H)‐ones and Thiazolo[3,4‐a]quinoxalin‐4(5H)‐ones.

88. PDCT-09. HYPERMUTATION AND NEOANTIGEN FORMATION IS DIAGNOSTIC AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN CHILDHOOD BIALLELIC MISMATCH REPAIR DEFICIENT BRAIN TUMORS

89. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

90. LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY

91. HG-53HYPERMUTATION AND NEOANTIGEN FORMATION PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN CHILDHOOD BIALLELIC MISMATCH REPAIR DEFICIENT GLIOBLASTOMA

92. LG-46INFERIOR OUTCOME AND POOR RESPONSE TO CONVENTIONAL THERAPIES IN PEDIATRIC LOW-GRADE GLIOMAS HARBORING THE BRAF V600E MUTATION

93. LG-58THERAPEUTIC IMPLICATIONS OF MOLECULAR BIOMARKERS IN INFANTS WITH PEDIATRIC LOW-GRADE GLIOMA

94. LG-68THE GENETIC AND CLINICAL LANDSCAPE IN PEDIATRIC LOW GRADE GLIOMA; PRELIMINARY RESULTS FROM PLGG TASKFORCE

96. Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.

97. Sa2045 Tumor Spectrum, Diagnostic Tools and Survival in Patients With Biallelic Mismatch Repair Gene Deficiency (BMMRD) Syndrome: Report From the International BMMRD Consortium

99. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low‐grade glioma.

Catalog

Books, media, physical & digital resources